Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | ANPEP | P15144 | 3/20 | 0.46 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.46 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.46 |
| ▸ | LARS1 | Q9P2J5 | 3/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CIT | O14578 | 1/20 | 0.35 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7412900 | 1.00 | SLC7A5 (0.50) | SLC7A5ANPEPRNPEPDNPEPLARS1 | |
| Hydrochloric Acid SCHEMBL7384486 | 0.98 | SLC7A5 (0.48) | SLC7A5ANPEPRNPEPDNPEPLARS1 | |
| SCHEMBL3160891 | 0.84 | SLC7A5 (0.47) | SLC7A5ANPEPRNPEPDNPEPLARS1 | |
| SCHEMBL27532729 | 0.84 | SLC7A5 (0.47) | SLC7A5ANPEPRNPEPDNPEPLARS1 | |
| SCHEMBL24155348 | 0.82 | SLC7A5 (0.45) | SLC7A5ANPEPRNPEPDNPEPLARS1 | |
| SCHEMBL29981834 | 0.82 | SLC7A5 (0.50) | SLC7A5ANPEPRNPEPDNPEPLARS1 | |
| SCHEMBL6791430 | 0.80 | CTSC (0.51) | SLC7A5ANPEPRNPEPDNPEPLARS1 | |
| SCHEMBL6592558 | 0.79 | SLC7A5 (0.39) | SLC7A5ANPEPRNPEPDNPEPLARS1 | |
| SCHEMBL12234245 | 0.79 | ECE1 (0.36) | POLB | |
| SCHEMBL22369843 | 0.79 | MAPT (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11325924-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-11242327-B2 | Analgesic compounds | RECURIUM IP HOLDINGS, LLC (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210228523-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-07-29 | — | — | US | disclosed |
| US-20210047347-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-02-18 | — | — | US | disclosed |
| US-10912750-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200270221-A1 | ANALGESIC COMPOUNDS | KTHERA, LLC | 2020-08-27 | — | — | US | disclosed |
| US-10752644-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10414782-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20190048029-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2019-02-14 | — | — | US | disclosed |
| US-20170114080-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170114080-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2017-04-27 | — | — | US | disclosed |
| EP-0960108-A1 | MATRIX METALLOPROTEINASE INHIBITORS | PHARMACIA & UPJOHN S.p.A. (IT) | 1999-12-01 | — | — | EP | disclosed |
| WO-1998033788-A1 | MATRIX METALLOPROTEINASE INHIBITORS | PHARMACIA & UPJOHN S.P.A. (IT) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270221-A1 | ANALGESIC COMPOUNDS | INA, IK, ACHE | SLC7A5 3807/4885ANPEP 2457/4885RNPEP 3720/4885 |
| US-20210228523-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | SLC7A5 2349/4885ANPEP 4158/4885RNPEP 4677/4885 |
| US-11242327-B2 | Analgesic compounds | INA, IK, ACHE | SLC7A5 3807/4885ANPEP 2457/4885RNPEP 3720/4885 |
| US-20170114080-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | SLC7A5 2349/4885ANPEP 4158/4885RNPEP 4677/4885 |
| US-20210047347-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | SLC7A5 2349/4885ANPEP 4158/4885RNPEP 4677/4885 |
| US-10912750-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | SLC7A5 2349/4885ANPEP 4158/4885RNPEP 4677/4885 |
| US-20190048029-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | SLC7A5 2349/4885ANPEP 4158/4885RNPEP 4677/4885 |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | SLC7A5 2349/4885ANPEP 4158/4885RNPEP 4677/4885 |
| US-10752644-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | SLC7A5 2349/4885ANPEP 4158/4885RNPEP 4677/4885 |
| US-10414782-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | SLC7A5 2349/4885ANPEP 4158/4885RNPEP 4677/4885 |
| US-11325924-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | SLC7A5 2349/4885ANPEP 4158/4885RNPEP 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.